George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
First announcement in a while and has to be good news.
New model and client paying for it so expands range and enables only HVO to offer model so unique.As this virus is hard to do a normal field trial the use of a HC model is ideal for Go/ No go decision.
Not surprised there is no value attached as client will want to remain hidden and commercial sensitivity but we know roughly cost of developing and manu of CHIM and running a 36 bed zHC trial so we can guess but firstly they have to develop model and go from there.
Most will be 2024 revenue so has be good and will get an update at some stage
Hi Douve,
Theoretically they should have parity hence my arbitrage comment but you have to take into account that both on Nasdaq and AIM you can have other influencers such as “ speculation “ and excitement over different bits of news and you have all the normal games so US hedge funds buying and selling ADRs for their own ends.
So depends on who takes the ADRs.As Bermuda says the US is much more financially savvy re bio pharma but SCLP will be a very small fish in a huge pool and unless it hires good US IR firms to spread the message then it is hard to predict the SP movement.
However LD did say a Nasdaq listing would be considered on good results and that will determine outcome here and I am confident they will make right call.
If a Glycan deal happened that would be great but I presume NASDAQ is being touted as a way of taking Modi 1 forward without future dilution of a deal
Evening Bermuda,
Have not listened to I/ view yet so not sure if more context given to recruitment but would have thought getting a BDO would not have been that difficult unless they were after quite a Senior Appointment when you can understand why they may have had sone difficulty.
If that is the case plus the as you say long overdue CFO then that could indicate a clear attempt to support LD and improve the “ commercial” side of SCLP
Morning Douve.
Depends on listing so if a dual listing which I would expect then nothing just additional shares get issued in US and then apart from arbitrage then nothing changes.
If a single US listing which would totally surprise me then you would get offered a swap at sone agreed rate and then you decide to sell or hold.
Don’t forget we are already listed in Frankfurt if memory serves me right and that has no effect here but that is so lightly traded whereas even though SCLP would be dwarfed on Nasdaq it will hopefully attract much wider institutional interest
Moonparty.
Can’t remember if they have enough allocation to issue new shares this year but clearly on the agenda and we will all have to look for clues like any shelf registration/appointment of US outfits/ advisors like HC Wainwright etc .
Next Modi update is eagerly awaited as we can better judge the potential and bank of data must be getting to an interesting inflection point in the near future.
Not sure JB I can think of at least 3 Biopharma that had a AIM and Nasdaq dual listing all with Market caps lower or similar to SCLP.
Makes sense to me to consider it if results are very good and provides a good exit strategy for major SH if they want the opportunity
JB any threshold price on Nasdaq is immaterial to current SP as they would simply list as ADRs which will have a “ consolidated SP. But good to see publicity in a major Sunday and the Nasdaq but was the only new bit as far I as I could see.
In response to your query the only official possibility of “ formal success” regarding the trial is this bit.
The Phase IIa expansion cohorts of the master protocol is designed with a Simon two-stage methodology, with an interim analysis for futility based on RECIST 1.1 ...
Normally an interim analysis would be in order of 75% of trial patients completed but as you can see this is only in the p2A bit so is in fact a sub set where the trial could be finished early.
This would be fantastic news but is some way off but any successful update would be most welcome as this would be indicative of progress so far.
Hi hope you are all enjoying B/H.
Not sure if this adds anything as from a couple of years ago but may be useful as background.
https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwi83NT4upr_AhXKRkEAHe7wB2gQFnoECDEQAQ&url=https%3A%2F%2Fwww.interpressnews.ge%2Fen%2Farticle%2F115008-statement-by-green-capital-and-zaza-mamulaishvili-aims-to-mislead-the-public%2F&usg=AOvVaw2h6t6vol6_dhHQkUv7XcLG
WTP there have been issues with BBC NW news this morning so we have had London and Look North today already so have not seen article on locally.
Hiwever I have been looking fir a few weeks so nothing on local TV AFAIK.
By coincidence I am in Widnes today :)
I know the Nomad had some issues with FRR ahead of the delisting but think it was the publication of the “ court documents” that highlighted some blatant misinformation that was the final step
Hi LL,
I honestly don’t believe that RM will be in the slightest bit interested in making a takeover bid for SCLP as they are an investment/ hedge fund and SCLP have many different platforms so making a complete takeover by anyone will be difficult.
The taking of control of Redx was a totally different situation and I don’t mean the diversified platforms are not valuable just they will have different value to different people not all to the same entity if that makes sense.
Hi ZZ it was my Friday ritual after coming back from the pub and the wife never understood when I seemed more keen to look on my I Pad than go to bed.
I have not checked the Cayman Court lists for years and she now says to me don't come to bed but there is nothing to stay up for lol
Thanks Zeron it was Justice Kawarley and Looed yes still a way to go and unpredictable outcomes as the one big lesson here is to expect the unexpected but at least there is some ” Hope “ though sone will shudder at the mention of that name.
I have long given up on who is right in this scenario and view any return here as a totally unexpected but welcome bonus whereas others will be seeking redress and the promised return for all their suffering and there are I am sure some real tales of heartbreak here.
What prompted my post as well as checking in was my Friday night/Saturday morning ritual of checking the Cayman Gazette and Court proceedings for updates
Morning and thanks to all who have updated us with the latest developments and especially Looed.Despite the obvious increase in positive sentiment I won’t get too excited until some concrete news and a real willingness by FRR to engage with SH about the current and future situation.The real change that seems to have occurred is the now apparent recognition brought about by whatever means legal or financial that the main adversaries need to work together to secure sone type of outcome.I just wish they had heeded the words of the wise Judge in the Caymans( can’t remember his name) who tried to bang the heads together some years ago as may have saved all parties including the long suffering SH a lot of grief. Enjoy the w/ end all
Completely agree Burble that would remove any speculation about when updates would be given and keep SH regularly informed.Of course these planned regular updates would also be supplemented by the normal newsworthy RNSs which are subject only to the normal timeline.
SCLP have a broad enough pipeline to do this as does not have to be any more than a brief update as other Companys do.
It is just a feature of small Biopharma that only seem to think they need to keep investors happy by releasing material news or subject to normal interim and full results touchpoints
Johnny has given an excellent summary of the Modify trial and of course there can be an update at any time and we are all keen to know the latest news as we believe the Science will generate the game changing data.
Bojo I can only think of one AIM Biopharma that gives regular updates ie every time the dose rate increases and a different cohort is initiated and traditionally SCLP has never given what I would call regular updates apart from the normal FPI/LPO and the actual final results etc.
This p1 trial is a very comprehensive one with lots of different cohorts involving different combinations and indications and apart from the universal safety data presumption common across different cohorts the efficacy data will be based on relatively low numbers and I just don’t feel that SCLP will be keen to update the market until they are in a position to provide pretty conclusive data and to me that will be a while.
They also as BS says have an interim analysis as part of the protocol and normally if you have that you are pretty confident but equally it provides a planned analysis and prepared. update point in advance.
None of us can be certain but I just counsel against the ebb and flow of expectations that have been observed recently and during the Covid trial and am happy to be patient confident in the Science delivering the results which will rerate the SP but there is a long way to go imo.